US FDA Issues Final Guidance On Cybersecurity In Medical Devices

Maryland: The FDA has issued the final guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket SubmissionsThe guidance replaces Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, issued on October 2, 2014.

This document provides recommendations on medical device cybersecurity considerations, device design and labeling, and what information to include in premarket submissions. “These recommendations are intended to promote consistency, facilitate efficient premarket review and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats,” the FDA states.

The guidance emphasizes that cybersecurity is part of device safety and the quality system requirements found in 21 CFR Part 820, which may be relevant at the premarket stage, postmarket stage or both. It provides recommendations on:

 

  • How connected devices should be tested and validated against breaches that affect multiple connected devices.
  • Provides labeling recommendations for devices with cybersecurity risks.
  • Recommends that companies develop cybersecurity management plans that communicate how they will identify and communicate postmarket vulnerabilities in accordance with 21 CFR 820.100.
  • Recommends that manufacturers provide an updateability and patchability view that describes the end-to-end process that permits software updates and patches to be provided/deployed once the device is in the field.

The guidance recommends that manufacturers use device design processes such as those described in the QS regulation to support secure product development and maintenance. But, to preserve flexibility, they may use other existing frameworks that satisfy the QS regulation and align with FDA’s recommendations for using a Security Product Development Framework (SPDF). Possible frameworks to consider include, but are not limited to, the medical device-specific framework that can be found in the Medical Device and Health IT Joint Security Plan (JSP) 30 and IEC 81001-5-1 or in ANSI/ISA 62443-4-1 Security for industrial automation and control systems Part 4- 1: Product security development life-cycle requirements.

Related Posts

Over-the-counter sale of cough syrup barred

Following the Drugs Rules amendment, lozenges, pills, and tablets for cough will still be available over the counter; 24 children in M.P. died after consuming adulterated cough syrup last year…

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Mumbai: On Tuesday, the FDA said it had sealed a cosmetic manufacturing factory in Bhiwandi for allegedly misleading consumers on e-commerce platforms by labelling its products as sulfate-free and paraben-free. The stock…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over-the-counter sale of cough syrup barred

Over-the-counter sale of cough syrup barred

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

No cough syrups without a doctor’s prescription – New rules announced

No cough syrups without a doctor’s prescription – New rules announced

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing